Wandercraft, a Paris-based robotics company, announced the U.S. commercial launch of Eve on September 17, 2026, calling it the world’s first self-balancing personal exoskeleton for home use. The device received FDA clearance in August 2026 for wheelchair users living with spinal cord injuries, and unlike earlier home exoskeletons on the market, Eve carries no restriction based on the neurological level of a user’s injury. CEO and co-founder Matthieu Masselin called the clearance \”one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers and partners who helped make it possible.\” The launch marks a turning point for a company that has spent nearly a decade building balance-control robotics, and it lands at a moment when AI-driven physical devices are increasingly crossing over from hospital rehab gyms into patients’ living rooms.
What Eve Actually Does
Eve is a wearable, motorized exoskeleton that straps onto a user’s legs and torso, using what Wandercraft describes as physical AI-powered self-balancing technology to keep the wearer upright and stable without the crutches or walking poles that competing devices typically require. Because the system manages balance automatically, users steer with a handheld controller while keeping both hands free to carry objects, prepare food, or open doors. The device is intended for use on level indoor surfaces and adjoining open-air areas such as patios and terraces, under the supervision of a trained companion. Wandercraft says Eve is meant to complement a wheelchair rather than replace it, giving users additional opportunities to stand, walk, turn, and reach throughout the day. Fitting is individualized: the company sizes Eve to users up to 220 pounds and 6 feet 4 inches, within set ranges for thigh length, leg length, pelvis width, and joint mobility, and new users complete five two-hour training sessions over at least a week before taking the device home.
The AI Behind the Balance
Wandercraft’s balancing software is the product of what the company describes as billions of simulations combined with tens of millions of real-world steps logged by its earlier clinical device, the Atalante X, which has been deployed in more than 100 rehabilitation and research centers worldwide and now logs over 1 million patient steps a month. That accumulated step data trains and refines the control algorithms that let Eve’s joints continuously adjust to a wearer’s shifting center of gravity, in effect learning to walk the way a person does rather than following a fixed, pre-programmed gait. Earlier this year, Wandercraft also won a second FDA clearance for Atalante X that expanded its approved indications to spinal cord injuries from levels C4 to L5 and to multiple sclerosis, adding joint-specific motor assistance and step-length adjustments in 5% increments. A multicenter study spanning 547 training sessions with high-level spinal cord injury patients supported that expanded clearance, and Wandercraft says three-site clinical trials of Eve itself found participants reported improvements in health status, psychological well-being, endurance, lower-limb spasticity, sitting balance, sleep quality, and bladder and bowel function.
Who Backed the Bet
Wandercraft closed a $75 million Series D funding round in June 2025, capital that helped push Eve through FDA review and into commercial production. The company has built its business in two tiers: Atalante X for clinics and rehabilitation centers, and now Eve for individual, at-home ownership. More than 5 million Americans live with some form of paralysis, including hundreds of thousands with spinal cord injuries, a population Wandercraft is positioning as the core market for Eve. On reimbursement, the company points to Medicare’s DMEPOS program, which has covered personal exoskeletons under billing code K1007 since 2024, and says its own access team will help patients and clinicians navigate documentation, prior authorization, and financing for those who choose to self-pay.
The Bigger Context: Exoskeletons Go Home
Eve enters a market that has been slowly maturing since the FDA first cleared a personal exoskeleton, ReWalk, for home and community use back in 2014, followed by Ekso Bionics’ Indego Personal in 2016. Those two devices have carried price tags averaging over $100,000, and while Medicare’s 2024 coverage decision set a lump-sum payment of roughly $91,000 for the ReWalk Personal, that still leaves patients responsible for a meaningful out-of-pocket balance unless secondary insurance fills the gap. The broader trend industry-watchers point to is exoskeletons moving from research curiosities into reimbursable medical equipment, with AI-driven balance control now the feature separating newer entrants like Eve from earlier, crutch-assisted designs. Advocacy groups such as the Christopher & Dana Reeve Foundation have tracked this shift closely, framing personal exoskeletons as a real but still-limited option: FDA-cleared and increasingly covered, yet expensive, physically demanding, and not appropriate for every injury level.
Where the Skepticism Lives
Clinicians and rehabilitation specialists who follow the exoskeleton field caution against overstating what devices like Eve can deliver. Coverage from outlets tracking the space, including Shield HealthCare’s spinal cord injury community reporting, has repeatedly framed exoskeletons as \”hype versus reality\”: genuinely useful for standing, circulation, and short-distance mobility, but not a substitute for a wheelchair, not usable on uneven terrain or stairs without help, and requiring a trained companion nearby at all times for safety. Cost remains the single biggest access barrier industry analysts cite, since even with Medicare’s roughly 80% reimbursement rate, patients can still face five-figure remaining balances, and prior-authorization documentation requirements have historically slowed approvals for competing devices like ReWalk. Wandercraft has not yet disclosed Eve’s list price, leaving open how it will compare with the six-figure costs of its established rivals, or how quickly private insurers beyond Medicare will follow suit in covering it.
What Comes Next
Wandercraft expects Medicare reimbursement eligibility for Eve to be finalized within 60 to 90 days of its FDA clearance, and the company says its access team is already working with early patients on financing and clinician coordination as the device reaches its first U.S. homes this fall. If Eve performs as promised at scale, it could pressure ReWalk and Ekso Bionics to accelerate their own AI-balancing upgrades, while giving payers new leverage to negotiate pricing across the category. For the spinal cord injury community, the more immediate test will be simpler: whether an AI system trained on millions of recorded steps can reliably keep a person upright in a kitchen or a hallway, day after day, without a specialist standing by to catch them.
Photo: Mikhail Nilov / PEXELS via Pexels
